Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01132 ...
Drug Name Pioglitazone
Molecular Weight 356.439
Molecular Formula C19H20N2O3S
CAS Number 111025-46-8
SMILES CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
External Links
DRUGBANK DB01132
T3DB T3D4981
PubChem Compound 4829
PDR 556
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Melting Point 193.0 ℃ 193-194 ℃ Al-Majed, A. et. al.
pKa 5.19 - 5.19 - Al-Majed, A. et. al.

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
C Max 1600.0 ng/ml 1.6±0.2 mcg/ml PO, oral; The Pharmacological Basis of Therapeutics
C Max 400.0 ng/ml 0.4±0.2 mcg/ml PO, oral; Active metabolite; The Pharmacological Basis of Therapeutics
C Max 1400.0 ng/ml 1.4±0.5 mcg/ml PO, oral; Active metabolite; The Pharmacological Basis of Therapeutics
T Max 2.0 h 2 h PO, oral; DRUGBANK
T Max 3.5 h 3-4 h PO, oral; food; food ↑ ; DRUGBANK
T Max 3.5 h 3.5(1-4) h PO, oral; The Pharmacological Basis of Therapeutics
T Max 11.0 h 11(2-48) h PO, oral; Active metabolite; The Pharmacological Basis of Therapeutics
T Max 11.0 h 11(4-16) h PO, oral; Active metabolite; The Pharmacological Basis of Therapeutics
Tss 168.0 h 7 day PO, oral; Active metabolite; DRUGBANK
Clearance 6.0 L/h 5.0-7 L/h apparent clearance; PO, oral; DRUGBANK
Clearance 0.0720 L/h/kg 1.2±1.7 ml/min/kg apparent clearance; PO, oral; normal,healthy; Male, men; patients; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.63 L/kg 0.63±0.41 L/kg Apparent volume of distribution; DRUGBANK
Volume of Distribution 0.63 L/kg 0.63±0.41 L/kg Apparent volume of distribution; PO, oral; normal,healthy; Male, men; patients; The Pharmacological Basis of Therapeutics
Half-life 5.0 h 3-7 h elimination half-life; DRUGBANK
Half-life 20.0 h 16-24 h elimination half-life; DRUGBANK
Half-life 11.0 h 11±6 h The Pharmacological Basis of Therapeutics
Half-life 29.0 h 29 h at steady state; Metabolite; The Pharmacological Basis of Therapeutics
Half-life 27.0 h 27 h at steady state; Metabolite; The Pharmacological Basis of Therapeutics
Toxicity TDLo 24.0 mg/kg 24.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity TDLo 3.0 mg/kg 3.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Eliminate Route 22.5 % ~15-30 % Urinary excretion; PO, oral; DRUGBANK
Eliminate Route 0 % ~0 % Urinary excretion; normal,healthy; type 2 diabetes; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 99.0 % >99 % plasma proteins; human, homo sapiens; DRUGBANK
Protein Binding 99.0 % >99 % normal,healthy; type 2 diabetes; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 45.0 mg/day 45 mg/day PO, oral Actos pioglitazone PDR
Max dose for elderly 45.0 mg/day 45 mg/day PO, oral Actos pioglitazone PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1